Relapsed/refractory patients

ASCO 2019 | Safety and efficacy of D-Rd in R/R multiple myeloma

L: English

At ASCO 2019, Chicago, US, the Multiple Myeloma Hub were delighted to interview Jonathan L. Kaufman, Winship Cancer Institute of Emory University, Atlanta, US, about the safety and efficacy of the D-Rd regimen; daratumumab + lenalidomide + dexamethasone. The POLLUX study, recruited patients with relapsed/refractory multiple myeloma. This is an updated analysis, focusing on cytogenetics. The results found that high-risk patients significantly benefited from the addition of daratumumab to lenalidomide + dexamethasone. This was also seen in the standard-risk group indicating all cytogenetics subgroups benefited.